Published in Rheumatol Int on January 01, 1984
Complement fixation by anti-dsDNA antibodies in SLE: measurement by radioimmunoassay and relationship with disease activity. Ann Rheum Dis (1986) 0.92
Immunoglobulin G subclass distribution of autoantibodies in systemic sclerosis, primary biliary cirrhosis, and overlap syndromes. Ann Rheum Dis (1987) 0.91
Immune complex signatures of patients with active and inactive SLE revealed by multiplex protein binding analysis on antigen microarrays. PLoS One (2012) 0.87
Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell (1999) 5.01
Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med (1988) 4.67
Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res (1986) 2.74
Intermediate filaments anchor the nuclei in nuclear monolayers of cultured human fibroblasts. Nature (1978) 2.28
Expression of intermediate filaments in cultured cells. J Cell Sci (1981) 2.25
Monoclonal antibodies to a nuclear protein (PCNA/cyclin) associated with DNA replication. Exp Cell Res (1987) 2.13
Isolated congenital heart block. Long-term outcome of mothers and characterization of the immune response to SS-A/Ro and to SS-B/La. Arthritis Rheum (1993) 1.96
Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis. Ann Rheum Dis (1992) 1.86
Human smooth muscle autoantibodies reacting with intermediate (100 A) filaments. Nature (1977) 1.82
Raised serum levels of cachectin/tumor necrosis factor alpha in renal allograft rejection. J Exp Med (1987) 1.80
Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol (1997) 1.74
Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int (2001) 1.53
Autoantibodies in infectious mononucleosis have specificity for the glycine-alanine repeating region of the Epstein-Barr virus nuclear antigen. J Exp Med (1987) 1.50
Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol (1993) 1.46
Autoantibody to "intermediate filament" in infectious mononucleosis. Clin Immunol Immunopathol (1979) 1.45
Circulating tumour necrosis factor-alpha (cachectin) in myocardial infarction. J Intern Med (1989) 1.44
The detection of human antibodies against cytoskeletal components. J Immunol Methods (1984) 1.43
Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog (1996) 1.41
Antibodies to cytoplasmic intermediate filaments in rheumatic diseases. J Rheumatol (1983) 1.41
Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis. Clin Nephrol (1995) 1.39
Immunoglobulins (E,M,G) and complement in the connective tissues of the thyroid in Graves's disease. N Engl J Med (1972) 1.31
A solid phase enzyme-linked immunosurbent assay (ELISA) for the demonstration of antibodies against denatured, single-stranded DNA in patient sera. Scand J Immunol (1978) 1.29
Glial fibrillary acidic protein and intermediate filaments in human glioma cells. Acta Neuropathol (1979) 1.29
Risk factors for mortality in Type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4. Diabetologia (1998) 1.25
Gastro-intestinal disturbances in patients with severe rheumatoid arthritis. Acta Med Scand (1970) 1.24
Characterization of the DNA-synthesizing cells in rheumatoid synovial tissue. Scand J Rheumatol (1978) 1.22
Reduced amyloid-A-degrading activity in serum in amyloidosis associated with rheumatoid arthritis. Br Med J (Clin Res Ed) (1982) 1.20
Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy. Arthritis Rheum (1996) 1.17
Purification of filaggrin from human epidermis and measurement of antifilaggrin autoantibodies in sera from patients with rheumatoid arthritis by an enzyme-linked immunosorbent assay. Int Arch Allergy Immunol (1998) 1.17
Characterization of the immunocompetent cells of rheumatoid synovium from tissue sections and eluates. Arthritis Rheum (1981) 1.17
Marker antibodies of rheumatoid arthritis: diagnostic and pathogenetic implications. Semin Arthritis Rheum (1994) 1.14
Immunoturbidimetry of albumin and immunoglobulin G in urine. Clin Chem (1982) 1.13
Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum (1989) 1.12
Proliferating cell nuclear antigen (PCNA)/cyclin in activated human T lymphocytes. J Immunol (1987) 1.11
Antifilaggrin antibodies in recent-onset arthritis. Scand J Rheumatol (1999) 1.11
Characterization of human smooth muscle autoantibodies reacting with cytoplasmic intermediate filaments. Clin Immunol Immunopathol (1978) 1.10
Letter: Negative complement-fixation tests as an immunopathological finding. Lancet (1974) 1.10
Tumor necrosis factor in children with malignancies. Cancer Res (1990) 1.09
Decreased urinary excretion of vascular endothelial growth factor in idiopathic membranous glomerulonephritis. Kidney Int (2000) 1.09
Smooth muscle antibodies of actin and "non-actin" specificity. Clin Immunol Immunopathol (1978) 1.09
Biopsy diagnosis of amyloidosis in rheumatoid arthritis. Malabsorption caused by intestinal amyloid deposits. Gastroenterology (1972) 1.07
Release of TGF-beta 1 and VEGF in tears following photorefractive keratectomy. Curr Eye Res (1997) 1.07
Antibodies to retroviral proteins in autoimmune connective tissue disease. Relation to clinical manifestations and ribonucleoprotein autoantibodies. Arthritis Rheum (1992) 1.07
Association of autoantibodies to filaggrin with an active disease in early rheumatoid arthritis. Ann Rheum Dis (2001) 1.07
Acute phase response in dairy cows with experimentally induced Escherichia coli mastitis. Acta Vet Scand (1999) 1.07
Faecal microbial flora and disease activity in rheumatoid arthritis during a vegan diet. Br J Rheumatol (1997) 1.06
Rheumatoid arthritis terminating in plasmocytoma. Acta Med Scand (1970) 1.06
Fistula of the thoracic duct as immunosuppressive treatment in rheumatoid arthritis. Acta Med Scand (1970) 1.05
Risk factors and markers associated with proliferative retinopathy in patients with insulin-dependent diabetes. Diabetes (1986) 1.04
Prevalence and mortality rates of systemic lupus erythematosus and causes of death in SLE patients in Finland. Scand J Rheumatol (1985) 1.04
Lymphocyte infiltrations of the gastric mucosa in Sjögren's syndrome. An immunoperoxidase study using monoclonal antibodies in the avidin-biotin-peroxidase method. Arthritis Rheum (1983) 1.03
Profiles of antinuclear antibodies in chronic active hepatitis, primary biliary cirrhosis and alcoholic liver disease. Liver (1984) 1.03
Human tear fluid PDGF-BB, TNF-alpha and TGF-beta1 vs corneal haze and regeneration of corneal epithelium and subbasal nerve plexus after PRK. Exp Eye Res (2001) 1.03
Atrophic gastritis in Sjögren's syndrome. Morphologic, biochemical, and immunologic findings. Arthritis Rheum (1985) 1.03
Serum hyaluronate level as a predictor of radiologic progression in early rheumatoid arthritis. Arthritis Rheum (1991) 1.02
Increased release of tumour necrosis factor-alpha in human tear fluid after excimer laser induced corneal wound. Br J Ophthalmol (1997) 1.01
Mechanism of reduced amyloid-A-degrading activity in serum of patients with secondary amyloidosis. Lancet (1982) 1.00
Correlation of persistently high serum amyloid A protein and C-reactive protein concentrations with rapid progression of secondary amyloidosis. Br Med J (Clin Res Ed) (1983) 0.99
Urinary transforming growth factor-beta 1 in membranous glomerulonephritis. Nephrol Dial Transplant (1997) 0.99
Fetal outcome in women with primary Sjögren's syndrome. A retrospective case-control study. Clin Exp Rheumatol (1995) 0.98
Type I collagen degradation product in serum of patients with early rheumatoid arthritis: relationship to disease activity and radiological progression in a 3-year follow-up. Br J Rheumatol (1994) 0.98
Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Ann Rheum Dis (2001) 0.98
Prospect for an additional laboratory criterion for rheumatoid arthritis. Scand J Rheumatol (1993) 0.97
Glomerular IgA deposits in patients with celiac disease. Clin Nephrol (1990) 0.97
Extracorporeal irradiation of thoracic duct lymph as immunosuppressive treatment in rheumatoid arthritis. Scand J Rheumatol (1976) 0.96
Vascular changes in erythropoietic protoporphyria: histopathologic and immunohistochemical study. J Am Acad Dermatol (2000) 0.96
Sclerosis of the arteries of the extremities in rheumatoid arthritis. Acta Med Scand (1969) 0.96
Comparative study of serum amyloid-related protein SAA, C-reactive protein, and beta 2-microglobulin as markers of renal allograft rejection. Clin Nephrol (1984) 0.96
Serum immunoglobulins and the risk of rheumatoid arthritis. Ann Rheum Dis (1997) 0.95
Relationship between urinary sialylated saccharides, serum amyloid A protein, and C-reactive protein in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis (1982) 0.95
Cytoskeleton antibodies in chronic active hepatitis, primary biliary cirrhosis, and alcoholic liver disease. Hepatology (1983) 0.94
Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes. Diabetologia (1999) 0.94
Early rise in serum concentration of transferrin receptor induced by recombinant human erythropoietin in very-low-birth-weight infants. Pediatr Res (1994) 0.94
Reproductive health in women with systemic lupus erythematosus compared to population controls. Scand J Rheumatol (2009) 0.94
Resolution of renal amyloidosis secondary to rheumatoid arthritis. Acta Med Scand (1979) 0.93
Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis. Kidney Int (1995) 0.93
Acid phosphatase activity in rheumatoid synovia. Acta Med Scand (1968) 0.93
Human leukocyte collagenase: characterization of enzyme kinetics by a new method. Anal Biochem (1977) 0.92
Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol Int (1992) 0.92
Cellular fibronectin in rheumatoid synovium and synovial fluid: a possible factor contributing to lymphocytic infiltration. Scand J Immunol (1990) 0.92
Neurofilament antibodies in systemic lupus erythematosus. J Rheumatol (1986) 0.91
Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia (1993) 0.91
Complement C3 cleavage and cytokines interleukin-1beta and tumor necrosis factor-alpha in otitis media with effusion. Laryngoscope (2000) 0.91
Predominantly vascular amyloid deposition in the kidney in patients with minimal or no proteinuria. Clin Nephrol (1983) 0.91
Platelet-derived growth factor-BB (PDGF-BB) in tear fluid: a potential modulator of corneal wound healing following photorefractive keratectomy. Curr Eye Res (1997) 0.91
Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM. Diabetologia (1995) 0.91
Mesangial glomerulonephritis as an extra-articular manifestation of rheumatoid arthritis. Br J Rheumatol (1997) 0.90
High pleural fluid hyaluronan concentrations in rheumatoid arthritis. Eur Respir J (1999) 0.90
Renal biopsy in rheumatoid arthritis. Acta Med Scand (1967) 0.90